Status:
RECRUITING
Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients
Lead Sponsor:
Consorci Sanitari Integral
Conditions:
Acute Heart Failure (AHF)
Congestive Heart Failure(CHF)
Eligibility:
All Genders
18+ years
Brief Summary
Treatment of congestion is one of the main goals in patients hospitalized for acute heart failure. Nevertheless, current evidence shows that decongestion is often not achieved and that residual conges...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Patients hospitalized for new onset heart failure or worsening heart failure defined by:
- Symptoms classified as New York Heart Association class III or IV.
- Clinical or instrumental signs of volume overload (e.g., dyspnea with evidence of pulmonary congestion on X-rays or lung ultrasound, pitting edema, and jugular venous distension).
- Elevated NT-proBNP levels within the first 24 hours of admission (cutoff values: 450 ng/L for patients \< 50 years; \>900 ng/L for patients aged 50-75 years; \>1800 ng/L for patients \>75 years).
- Ability to provide informed consent.
Exclusion
- Known diagnosis of septicemia.
- Glomerular filtration rate \< 15 ml/min.
- Life expectancy \< 6 months.
- Active myocarditis.
- Heart transplant recipients.
- Patients with ventricular assist devices.
- Congenital heart diseases.
- Moderate-to-severe liver disease (Child-Pugh B-C).
- Patients that will not be followed up by the Heart Failure Unit.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06993220
Start Date
January 1 2025
End Date
January 1 2027
Last Update
July 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Complex Hospitalari Universitari Moisès Broggi
Sant Joan Despí, Barcelona, Spain, 08970